Evidence map›Paper›PMID 36319985›Full record

ArticleBMC cancer2022

Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.

Trine Husby, Håkon Johansen, Trond Velde Bogsrud, Kari Vekseth Hustad, Birte Veslemøy Evensen, Ronald Boellaard, Guro F Giskeødegård, Unn-Merete Fagerli, Live Eikenes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Trine HusbyDepartment of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks, 8905, Trondheim, Norway.
Håkon JohansenDepartment of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Trond Velde BogsrudPET-Centre, University Hospital of North Norway, Tromsø, Norway.
Kari Vekseth HustadDepartment of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Birte Veslemøy EvensenDepartment of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Ronald BoellaardDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
Guro F GiskeødegårdDepartment of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Unn-Merete FagerliDepartment of Oncology, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
Live EikenesDepartment of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks, 8905, Trondheim, Norway. live.eikenes@ntnu.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this prospective study was to investigate the prognostic value of metabolic tumor volume (MTV) and apparent diffusion coefficient (ADC) from baseline FDG PET/MRI compared to established clinical risk factors in terms of progression free survival (PFS) at 2 years in a cohort of diffuse large B-cell Lymphoma (DLBCL) and high-grade-B-cell lymphoma (HGBCL).

methodsThirty-three patients and their baseline PET/MRI examinations were included. Images were read by two pairs of nuclear medicine physicians and radiologists for defining lymphoma lesions. MTV was computed on PET, and up to six lymphoma target lesions with restricted diffusion was defined for each PET/MRI examination. Minimum ADC (ADC

resultsECOC PS scale ≥2 (p = 0.05) and ADC

conclusionsADC

Indexed as

Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinFluorodeoxyglucose F18HumansMagnetic Resonance ImagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyPrognosisProspective StudiesRadiopharmaceuticalsRetrospective StudiesTumor BurdenFluorodeoxyglucose F18RadiopharmaceuticalsApparent diffusion coefficientLymphomaMetabolic tumor volumePET/MRI

Identifiers

PMID36319985
PMCPMC9623965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.